Almirall reports increased core net sales growth in first quarter of 2023

Key takeaways:

• Almirall’s core net sales for the first quarter of 2023 have reached 232 million euros.
• The company reports robust business growth due to the 11.4% increase of European sales.

Almirall announced its financial results for the first quarter of 2023, which included a year-on-year, core net sales increase of 6% due to its European sales, according to a company press release.

The increase was a “solid start for Almirall,” according to company CEO and chairman Carlos Gallardo Piqué.

“We delivered an excellent operational performance that sets us on track to meet our 2023 guidance,” Gallardo Piqué said in the release.

The company reports business growth of 11.4% in Europe. Additionally, Almirall’s core net sales for the quarter have reached 232 million euros. Total earnings before interest, taxes, depreciation and amortization was 51.8 million euros, according to the release, which was a 13.1% decrease compared with the same quarter last year.

Growth drivers that contributed to Almirall’s performance include steady, year-on-year sale increases of Ilumetri, Klisyri and Wynzora.

The company continues to prepare for the launch of lebrikizumab for the treatment of atopic dermatitis. With a request for regulatory approval in the European Union submitted in October 2022, lebrikizumab is expected to receive a marketing authorization by the European Commission in late 2023, according to the release.